There are 3161 resources available
610O - Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
Presenter: Manish Patel
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Presenter: Kimmie Ng
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
1596O - Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
Presenter: Emily Grist
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA67 and 1596O
Presenter: Rana McKay
Session: Proffered paper session: GU tumours, prostate
Resources:
Slides
Webcast
Discussion
Session: YO Masterclass: Designing v2.0 clinical trials
Resources:
Webcast
719MO - A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer
Presenter: Elizabeth Lee
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
1079MO - Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
Presenter: Hildur Helgadottir
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
611O - Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Presenter: John Haanen
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
506O - Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO
Presenter: Marco Germani
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA26 and 506O
Presenter: Michel Ducreux
Session: Proffered paper session 2: GI tumours, lower
Resources:
Slides
Webcast